电邮这篇文章 
国内制药业的现状和发展前景
- 作者: Miroshnichenko Y.V.1, Perfiliev A.B.1, Shcherba M.P.1, Enikeeva R.A.1, Ovchinnikov D.V.1, Kostenko N.L.1, Rodionov E.O.2
-
隶属关系:
- Kirov Military Medical Academy
- Major Military Medical Administration
- 期: 卷 26, 编号 1 (2024)
- 页面: 129-140
- 栏目: History of medicine
- URL: https://journals.rcsi.science/1682-7392/article/view/255222
- DOI: https://doi.org/10.17816/brmma624836
- ID: 255222
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
本文介绍了在国外大型药品和医疗器械公司主导医药市场的情况下，2010 年代俄罗斯医疗和制药业的主要发展阶段。文章反映了欧盟、美国和其他一些不友好国家对俄罗斯非法采取的政治和经济限制措施，这些措施影响了本国医疗制药业的发展动态。为了统一药品生产和质量控制的方法，本文介绍了俄罗斯制药业向《药品生产质量管理规范》过渡的大规模改革阶段以及旨在实现制药业工业部门现代化的政府计划的实施情况。在完善药品标准化体系的框架内，介绍了研究期间出版的第十三、十四和十五版《俄罗斯联邦国家药典》的特点，S.M. 基洛夫军事医学院的工作人员参与了该药典的编写工作。反映了欧亚经济委员会合议庭批准的《欧亚经济联盟药典》的作用和目的。本文介绍了分阶段实施联邦目标方案、国家方案以及其他战略计划和国家非财政支助措施的情况，这些计划和措施使得药品和医疗器械的研发和生产领域的能力得到显著提高，并在所述期间增加了产量。可以发现，在作为行业“火车头”的医药集群的帮助下，以及在工业发展基金的帮助下建立生产创新型医疗产品的各种项目，在开发药品和增加药品生产方面发挥了重要作用，从而增加了国民经济综合体这些部门的投资吸引力。本文呢揭示了有关恢复生产药房活动的变革的本质，同时考虑到对患者治疗的个性化方法。对 2030 年之前的制药业发展战略进行了评估。
作者简介
Yuri V. Miroshnichenko
Kirov Military Medical Academy
编辑信件的主要联系方式.
Email: miryv61@gmail.com
ORCID iD: 0000-0002-3645-2071
SPIN 代码: 9723-1148
MD, Dr. Sci. (Pharm.), professor
俄罗斯联邦, Saint PetersburgAlexander B. Perfiliev
Kirov Military Medical Academy
Email: miryv61@gmail.com
ORCID iD: 0000-0002-9947-1296
SPIN 代码: 6843-2803
Cand. Sci. (Pharm.)
俄罗斯联邦, Saint PetersburgMaria P. Shcherba
Kirov Military Medical Academy
Email: marya.scherba@yandex.ru
SPIN 代码: 9840-4740
Cand. Sci. (Pharm.), associate professor
俄罗斯联邦, Saint PetersburgRimma A. Enikeeva
Kirov Military Medical Academy
Email: rimmaspec@mail.ru
ORCID iD: 0000-0002-6058-7187
SPIN 代码: 4917-6516
Cand. Sci. (Pharm.), associate professor
俄罗斯联邦, Saint PetersburgDmitrii V. Ovchinnikov
Kirov Military Medical Academy
Email: dv.ovchinnikov-vma@yandex.ru
ORCID iD: 0000-0001-8408-5301
SPIN 代码: 5437-3457
Scopus 作者 ID: 36185599800
MD, Cand. Sci. (Med.), associate professor
俄罗斯联邦, Saint PetersburgNatalya L. Kostenko
Kirov Military Medical Academy
Email: kostenkoNL@yandex.ru
SPIN 代码: 8559-7624
Cand. Sci. (Pharm.), associate professor
俄罗斯联邦, Saint PetersburgEvgeniy O. Rodionov
Major Military Medical Administration
Email: rodionov_eo@mail.ru
ORCID iD: 0000-0002-9992-7417
SPIN 代码: 9782-8532
MD, Dr. Sci. (Pharm.)
俄罗斯联邦, Moscow参考
- Nezhnikova EV, Maksimchuk MV. Pharmaceutical industry in Russia: problems and prospects of development. RUDN journal of economics. 2019;27(1):102–112. EDN: TFHWQO doi: 10.22363/2313-2329-2019-27-1-102-112
- Miroshnichenko YuV, Golubenko RA, Enikeeva RA. Modern aspects of the development of the pharmaceutical industry. Military medical journal. 2023;344(6):93–96. EDN: MMHUSK doi: 10.52424/00269050_2023_344_6_93
- Oborin MS. Problems and prospects of import substitution in the pharmaceutical industry. Bulletin NGIEI. 2021;(5):101–110. EDN: YPGGYL doi: 10.24412/2227-9407-2021-5-101-110
- Miroshnichenko YuV, Perfiliev AB, Kostenko NL, Enikeeva RA. Historical and medical-pharmaceutical aspects of the creation of a pharmacopeia. Bulletin of the Russian Military Medical Academy. 2022;24(1):219–230. EDN: XHKWJU doi: 10.17816/brmma89024
- Lin AA, Sokolova SV, Bol’shakova MV. Pharmaceutical market: implementation of the import substitution strategy (Russia, St. Petersburg). Problems of modern economics. 2017;(2):181–186. EDN: ZMYZJT
- Andreeva LV. The normative legal basis for the establishment of the common market of medicines of the Eurasian Economic Union. International Cooperation of Eurasian States: Politics, Economics, Law. 2016;(4):51–60. EDN: ZBEVGH
- Egorova DA. Drivers for the development of the pharmaceutical industry: global trends. Modern science: actual problems of theory and practice”, a series of “Economics and law”. 2023;(2):22–26. EDN: FIAENF doi: 10.37882/2223-2974.2023.02.12
- Zavyalova EB, Polozova DV. Development prospects of the Russian pharmaceutical industry in the modern context. International business. 2023;(2):64–78. EDN: HIARBN
- Umarov SZ, Khorunzhaya AA, Tikhonov AV. Analysis of the pharmaceutical industry digital transformation: positive and negative consequences. Pharmacoeconomics: theory and practice. 2023;11(2):64–65. EDN: ZWIZAW doi: 10.30809/phe.2.2023.40
- Gorobets MS. Pharmaceutical industry of the Russian Federation in the conditions of external sanctions. Bulletin of the Educational Consortium of the Middle Russian University. Series: economics and management. 2023;(21):75–77. EDN: GIDMXC
